BOSTON (TheStreet) --The first quarter earnings' reporting season for the biotech sector kicks off next week. Here are capsule earnings summaries and expectations for nine revenue-generating biotech stocks, including the large-cap group.

Amylin Pharmaceuticals ( AMLN)

Earnings date: April 19

Consensus estimate: Net loss of 29 cents a share on total revenue of $188.82 million.

Current 2010 guidance: None, pending the approval of Bydureon, the company's once-weekly injectable diabetes drug.

Stock performance YTD: up 64%

Key questions and highlights: First quarter results, including sales of Byetta, are less important to investors than the pending FDA approval of Bydureon. The FDA issued a complete response letter for Bydureon on March 15, requesting Amylin complete negotiations with the agency on the drug's label and a risk-management plan.

Biogen Idec ( BIIB - Get Report)

Earnings date: April 20

Consensus estimate: Adjusted earnings of $1.13 a share on total revenue of $1.12 billion.

Current 2010 guidance: Revenue growth in the mid-single digits, earnings (GAAP) greater than $3.71 a share, adjusted earnings greater than $4.55 a share.

Stock performance YTD: up 4%

Key questions and highlights: Worldwide Tysabri sales are expected to reach $306 million in the quarter (with revenue recorded by Biogen Idec of $230 million.) Investors will also be listening for management commentary about doctors shortening Tysabri therapy or introducing drug holidays -- all to mitigate the risk of the serious brain infection PML. Worldwide sales of Avonex are expected to total $595 milion. Biogen Idec is in the midst of a search for a new chief executive.

Gilead Sciences ( GILD - Get Report)

Earnings date: April 20, after market.

Consensus estimate: Adjusted earnings of 95 cents on total revenue of $2.05 billion.

Current 2010 guidance: Total product sales of $7.6-$7.7 billion.

Stock performance YTD: up 7%

Key questions and highlights: Earnings expectations for Gilead are always high because the company has a history of turning in strong quarterly numbers. With that said, prescription data suggests that U.S. Atripla sales may be tracking at or slightly below consensus, which could impact the current worldwide sales consensus of $726 million. Truvada sales worldwide are expected to total $680 million in the quarter. On the clinical data front, Johnson & Johnson ( JNJ) is expected to release phase III data on the Gilead-partnered HIV drug rilpivirine in the second quarter.

Vanda Pharmaceuticals ( VNDA - Get Report)

Earnings date: Marketing partner Novartis ( NVS) reports on April 20; Vanda hasn't set a date to announce first quarter earnings.

Consensus estimate: Vanda earnings of 7 cents a share on total revenue of $7.7 million.

Current 2010 guidance: No top-line or earnings guidance provided.

Stock performance YTD: Flat

Key questions and highlights: Novartis is Vanda's marketing partner for the schizophrenia drug Fanapt. While very early in the launch (Novartis began selling Fanapt in the middle of January), Vanda investors will be eager to see the drug's first quarter sales and hear any commentary on the launch from Novartis executives. Jefferies analyst Corey Davis is looking for $11 million in first-quarter Fanapt sales.

Genzyme ( GENZ)

Earnings date: April 21

Consensus estimate: Adjusted earnings of 34 cents a share on total revenue of $1.14 billion.

Current 2010 guidance: Adjusted earnings of $2.80-$3.20 a share on total revenue of $5.23 - $5.53 billion.

Stock performance YTD: up 6%

Key questions and highlights: Genzyme's first-quarter results matter little in the context of the larger manufacturing and regulatory issues impacting the company's future. Investors will be listening for updates on Genzyme's negotiations with the FDA over the manufacturing consent decree, the likelihood that the FDA approves Lumizyne on June 17, and any comment from management on the upcoming shareholder meeting and the proxy fight for board seats with activist investor Carl Icahn.

Amgen ( AMGN - Get Report)

Earnings date: April 21, after market.

Consensus estimate: Adjusted earnings of $1.24 a share on total revenue of $3.65 billion.

Current 2010 guidance: Adjusted earnings of $5.05 - $5.25 on total revenue of $15.1-$15.5 billion.

Stock performance YTD: up 7%

Key questions and highlights: As long as there are no major surprises, Amgen's first-quarter results will likely take a backseat for investors more focused on what the company says about the upcoming FDA approval (on July 25) and subsequent launch plans for the osteoporosis drug Prolia. Prescription tracking data suggests modest upside in sales of many Amgen drugs, including Aranesp (consensus $638 million) and Enbrel (consensus $849 million.)

Alexion Pharmaceuticals ( ALXN - Get Report)

Earnings date: April 22

Consensus estimate: Earnings of 33 cents a share on total revenue of $115.53 million.

Current 2010 guidance: Net product sales of $505 - $520 million. Adjusted earnings of $1.60 - $1.65 a share.

Stock performance YTD: up 12%

Key questions and highlights: Soliris sales are expected to reach $115 million in the first quarter. Investors will be listening for management guidance on Soliris' growth strategy beyond the U.S. and Europe.

Celgene ( CELG)

Earnings date: April 29

Consensus estimate: Adjusted earnings of 60 cents a share on total revenue of 756.9 million.

Current 2010 guidance: Adjusted earnings of $2.55 - $2.60 a share on total revenue of $3.2 - $3.3 billion. Revlimid sales are expected to be in the range of $2.1 - $2.2 billion.

Stock performance YTD: up 9%

Key questions and highlights: Celgene has been the best-performing stock in the large-cap biotech group, so a strong performance from Revlimid in the quarter ($497 million consensus) will be required to sustain the momentum. Celgene will be presenting important data on Revlimid as a maintenance treatment for multiple myeloma patients at June's American Society of Clinical Oncology annual meeting.

Allos Therapeutics ( ALTH)

Earnings date: First week of May (specific date not yet announced.)

Consensus estimate: Net loss of 22 cents a share on total revenue of $7.14 million.

Current 2010 guidance: No top-line or earnings guidance, but total operating costs and expenses of $120 - $130 million, excluding options expenses.

Stock performance YTD: up 30%

Key questions and highlights: Allos launched its lymphoma drug Folotyn in January. The Street expectations for this first quarter of sales is in the range of $7-$8 million.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.